Correvio Pharma Corp on Wednesday said it would explore options including putting itself up for sale, a day after a panel of experts advising the U.S. health regulator voted against approving its heart drug. The Canadian drugmaker’s U.S.-listed shares plunged 57% to 60 cents in trading before the bell. …read more
Source:: Yahoo Finance
